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Abstract
Background: Despite IFNα  has been used extensively in the treatment of multiple myeloma
(MM), there are also several reports suggesting that IFNα  may aggravate isease in some MM
patients. That means the effect of IFNα  on the growth of myeloma cells in vivo may be different.
In this study, we selected two human myeloma cell lines that vary remarkably in response to IFNα
and focused on elucidating the mechanism of differential IFNα  responsiveness.
Results: Sko-007 is a myeloma cell line whose growth is arrested by IFNα ; however, IFNα
promoted the proliferation of the other myeloma cell line U266. We observed that the growth-
stimulation effect of IFNα  on U266 cells did not result from up-regulation of the IL-6 receptors on
cell surface; while IFNα  treatment on Sko-007 cells significantly reduced gp130 expression.
Moreover, the transcription factors STAT3 and STAT1, which are involved in the JAK/STAT signal
transduction pathway, can be activated in both IFNα -stimulated and -inhibited myeloma cell lines;
while the activation of the protein kinase ERK, which is involved in the Ras/MAPK signal
transduction pathway, can be down-regulated in IFNα -arrested Sko-007 cells and up-regulated in
IFNα -stimulated U266 cells. In addition, both IFNα -induced growth-stimulation effect and the up-
regulated activation of ERK in U266 cells were efficiently inhibited by PD98059, the specific
inhibitor of MAPK/ERK kinase (MEK).
Conclusion: Myeloma cells responsiveness to IFNα  is heterogeneous and the activation state of
ERK in the Ras/MAPK signalling pathway mainly contributed to this difference.
Background
The typically growth-inhibitory action of Interferonα  (IF-
Nα ) has made it a commonly used therapeutic agent in
the treatment of a wide variety of human malignancies,
including multiple myeloma (MM) [1]. However, al-
though a considerable number of the clinical trials have
addressed the effectiveness of IFNα  on MM therapy [2],
other reports also showed that in some MM patients,
IFNα  can promote the proliferation of myeloma cells in
vivo and result in the development of aggressive plasma
cell leukemia (PCL) [3]. Therefore, the action of IFNα  on
MM cell growth is a matter of debate, and the mechanism
of this discrepancy is the topic of this study.
Interleukin-6 (IL-6) is the major growth and survival fac-
tor for myeloma cells. IFNα  and IL-6 clearly use distinct
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receptor complexes; however, both cytokines have been
shown to use two common signal transduction pathways
to mediate their biological activities. One is the janus ki-
nase-signal transducer and activator of transcription (JAK/
STAT) pathway which results to the activation of the pro-
tein tyrosine kinases JAKs and the transcription factors
STAT3 and STAT1; the other is the Ras-dependent mi-
togen-activated protein kinase (Ras/MAPK) pathway
which involves the subsequent activation of a series of ser-
ine/threonine kinases including extracucullar signal-regu-
lated kianse (ERK) [4,5]. In the previous report, we have
investigated in detail the mechanism of IL-6 signal trans-
duction in different human myeloma cell lines [6]. In this
study, we analyzed IFNα -induced activation of STAT3,
STAT1 and ERK in Sko-007 and U266 human myeloma
cell lines, which displayed overall different response to IF-
Nα . And we demonstrated the evidence that the activation
state of the Ras/MAPK in stead of the JAK/STAT signal
transduction pathway accounted mainly for the differen-
tial effect of IFNα  on myeloma cells.
Results
Myeloma cell lines are heterogeneous in response to IFNα
To determine the effect of IFNα  on the growth of myelo-
ma cells, MTT assay was firstly performed on four human
myeloma cell lines-Sko-007, U266, KM-3 and XG-7 [7].
The growth of three myeloma cell lines (Sko-007, KM-3
and XG-7) were significantly inhibited in the presence of
IFNα ; whereas IFNα  moderately promoted the prolifera-
tion of the forth myeloma cell line U266. Fig. 1 displayed
a concentration-dependent growth-inhibition and -stimu-
lation effect of IFNα  on Sko-007 and U266 cells, respec-
tively. This result supported the conclusion that there are
two distinct patterns of IFNα  response in human myelo-
ma cells.
Effect of IFNα  on the expression of two IL-6 receptor 
chains on myeloma cell surface
IL-6 is the major growth factor for myeloma cells. It has
been reported that the effect of many other growth-stimu-
lating or growth-inhibitory factors on myeloma cells is a
secondary consequence that is mediated by the regulation
on the expression or the activity of IL-6 or its receptors [4].
To determine whether a similar mechanism accounted for
the different effect of IFNα  on Sko-007 and U266 cells,
IFNα -treated and untreated cells were incubated respec-
tively with the specific antibodies to the two IL-6 receptor
chains, gp80 (IL-6R) and gp130, then FACS analysis was
performed. As shown in Table 1, the expression level (rep-
resented by both the average strength of fluorescence on
cell surface and the percentage of the positive cells) of
gp130 was down-regulated significantly in Sko-007 cells
with the treatment of IFNα  for 48 h, while there was no
obvious changes on IL-6R level at the same conditions.
This result indicated that growth-inhibition effect of IFNα
on Sko-007 cells was partially mediated by down-regulat-
ed expression of gp130 on cell surface. In contrast,
growth-stimulation of U266 cells in the presence of IFNα
did not involve any induction of IL-6R and gp130 expres-
sion. Taken these results together, we concluded that
IFNα -induced regulation of IL-6 receptors expression on
cell surface is not a common mechanism to mediate the
effect of IFNα  on myeloma cells.
Figure 1
Effect of IFNα  on the growth of Sko-0007 and U266 cells. 2 ×  103 Sko-007 or U266 cells/well were cultured in 96-well
tissue culture plates in the absence or presence of increasing concentrations of IFNα . After incubation for 48 h at 37°, MTT
was mixed into each well and the incubation was prolonged for another 6 h, then the dark blue crystal were dissolved in 100 µl
of 10% SDS in 0.01 N HCl. Absorbance was measured at 570 nm.
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Figure 2
Activation states of STAT3 and STAT1 in Sko-007 and U266 cells in the absence or presence of IL-6 or IFNα . 2
×  106 Sko-007 or U266 cells were left untreated or treated with IL-6 (10 ng/ml) or IFNα  (100 U/ml) for 10 min and lyzed in
cell lysis buffer. Then 30 µg cytoplasmic proteins were separated by 10% polyacrylamide-SDS gel and transferred elechtropho-
retically to Immobilon. After blocking with 5% dry milk, the membranes were blotted with anti-STAT3, STAT1, phospho-
STAT3 or phospho-STAT1 antibodies and the relevant HRP-labeled second antibodies. Immunoreactive proteins were visual-
ized using an enhanced chemiluminescence (ECL) detection system (Amersham, USA).
Table 1: Expression of IL-6R and gp130 on the surface of Sko-007 and U266 cells in the absence or presence of IFNα .
IFNα  (-) IFNα  (+)
%m e a n %m e a n
IL-6R 13.00 ± 1.21 20.57 ± 2.74 10.11 ± 0.96 19.80 ± 0.47
Sko-007
Gp130 99.06 ± 1.01 60.68 ± 1.70 65.77 ± 3.19* 34.21 ± 1.31*
IL-6R 1.50 ± 0.33 50.44 ± 2.09 0.92 ± 0.36 50.09 ± 4.28
U266
Gp130 8.66 ± 0.64 29.19 ± 2.13 9.33 ± 1.05 26.66 ± 0.63
2 ×  105 or cells were treated with or without IFNα  (100 U/ml) for 48 h and then subsequently incubated with anti-IL-6R or anti-gp130 antibodies 
for 30 min and with the relevant FITC-labeled second antibodies for 20 min. Cell samples were harvested and subjected to FACS analysis equipped 
with ModFitLT software. ''mean'' represents the average strength of fluorescence. ''%'' represents the percentage of the cells expressing target anti-
gen (positive cells). The p values were determined by paired t-test. *significantly different (p < 0.01) from the corresponding values in cultures with-
out IFNα .
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Activation of the transcription factors STAT3 and STAT1 
in myeloma cells stimulated by IFNα
JAK/STAT pathway is one of two common signal transduc-
tion pathways used by both IL-6 and IFNα  to mediate
their activities [4,5]. To address whether there exists any
difference in the activation of the JAK/STAT pathway in
Sko-007 and U266 cells stimulated by IFNα , immunoblot
assay was performed using anti-phospho-STAT3 and
phospho-STAT1 antibodies to detect the activation of the
transcription factors STAT3 and STAT1 in the JAK/STAT
pathway. As shown in Fig. 2, there was no activation of
STAT3 and STAT1 in unstimulated Sko-007 and U266
cells, while IL-6 and IFNα  can activate both two transcrip-
tion factors in the both two cell lines. Anti-STAT3 and
STAT1 antibodies blotting showed equal amount of
STAT3 and STAT1 proteins in untreated and IL-6 or IFNα -
treated cells. These results indicated that the activation of
the JAK/STAT pathway did not account for the different ef-
fect of IFNα  on Sko-007 and U266 cells.
Activation state of the protein kinase ERK in myeloma cells 
stimulated by IFNα
Ras/MAPK pathway is the other common signal transduc-
tion cascade used by both IL-6 and IFNα  [4,5]. In the pre-
vious report, we have proved that the survival of Sko-007
and U266 cells were mediated by the constitutive activa-
tion of this pathway in the presence of the autocrine IL-6
[7]. To analyze whether the activation of this pathway was
different in above two cell lines in the presence of IFNα , a
similar immunoblot assay was performed using anti-
phospho-ERK antibody to detect the activation state of the
protein kinase ERK, the most important kinase in the Ras/
MAPK pathway. As shown in Fig. 3, constitutive activation
of ERK can be observed in both Sko-007 and U266 cells in
the absence of IFNα ; and IFNα  simulation down-regulat-
ed ERK activation in Sko-007 cells and up-regulated ERK
activation in U266 cells. This result strongly suggested
that different regulation of the protein kinase ERK in the
Ras/MAPK signal transduction pathway might play a key
role in responding to IFNα  in Sko-007 and U266 cells.
PD98059 inhibited IFNα -induced growth-stimulation ef-
fect and up-regulation of ERK activation in U266 cells
To further confirm the result from Fig. 3, we next analyzed
whether the regulation on ERK activation can result to the
corresponding changes on the activity of IFNα  on myelo-
ma cells. As shown in Fig. 4, when IFNα -induced increase
of ERK activation in U266 cells was efficiently inhibited
by treatment of PD98059, the specific inhibitor of the up-
stream kinase of ERK, MAPK/ERK kinase (MEK), in the
Ras/MAPK pathway, IFNα -mediated growth-stimulation
effect was also decreased at the same conditions. This
finding confirmed the result that protein kinase ERK in
the Ras/MAPK pathway mainly contributed to the differ-
ential responsiveness of myeloma cells to IFNα .
Discussion
Up till now, the clinical value of IFNα  on multiple myelo-
ma therapy remains debatable due to the conflicting in
vivo results reported by different clinical groups [2,3].
Therefore in this study, we analyzed the responsiveness of
Figure 3
Activation state of ERK in Sko-007 and U266 cells in the absence or presence of IFNα . 2 ×  106 Sko-007 or U266
cells were left untreated or treated with IFNα  (100 U/ml) for 48 h and lyzed in cell lysis buffer. Then cytoplasmic proteins were
extracted and the expressions of phospho-ERK and ERK were determined by immunoblot assay as similar as in Fig. 2 except
using anti-ERK or phospho-ERK antibodies.
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a panel of human myeloma cell lines to IFNα  in vitro and
the mechanism of myeloma cells heterogeneous response
to IFNα .
The results in this study showed that IFNα  exerted differ-
ent effects on the growth of different myeloma cell lines.
The growth-inhibition effect of IFNα  was significant while
the growth-stimulation effect was moderate (Fig. 1). This
result is in accordance with the fact that IFNα  usually ex-
erts a strongly inhibitory or a slowly stimulatory effect on
the proliferation of myeloma cells in different patients
with MM [2,3].
To elucidate the mechanism responsible for the different
activity of IFNα  on myeloma cells, we firstly examined the
regulation of IL-6R and gp130 expression on cell surface
in the presence of IFNα , which may be one of the reasons
for the heterogeneous IFNα  responsiveness according to
the previous reports [8]. Interestingly, we only detected
down-regulated expression of gp130 in IFNα -arrested
Sko-007 cells, while not any changes on two IL-6 receptor
chains level in IFNα -stimulated U266 cells. Therefore, the
regulation of IL-6 receptors expression may not mainly ac-
count for the different effect of IFNα  on myeloma cells.
In the further study, we focused on investigating the acti-
vation states of IFNα -induced signal transduction path-
ways in myeloma cellls. We observed that both STAT3 and
STAT1 could be activated in the both two myeloma cell
lines irrespective of growth outcome upon IFNα  stimula-
tion; while the activation state of ERK correlated tightly
with the growth effect of IFNα  (Fig. 2, 3 and 4). That
means, the Ras/MAPK in stead of the JAK/STAT signal
transduction pathway mainly contributed to the different
response of myeloma cells to IFNα . Identification of the
target gene(s) regulated by protein kinase ERK in the Ras/
MAPK pathway in IFNα -arrested and stimulated myeloma
cells will be helpful to further elucidate the mechanism of
IFNα  on myeloma cells.
Conclusions
Our data in this study clearly demonstrated that IFNα  can
exert growth-stimulatory or -inhibitory effect on different
Figure 4
PD98059 inhibited IFNα -induced growth-stimulation effect and increase of ERK activation in U266 cells. (A)
U266 cells were left untreated or treated with IFNα  (100 U/ml) or pre-treated with PD98059 (50 µM) before IFNα  was
added. Then cytoplasmic proteins were extracted and the expressions of phospho-ERK and ERK were determined by immuno-
blot assay as same as in Fig. 3. (B) U266 cells (2 ×  106 /well) were cultured in 96-well tissue culture plates in the absence or
presence of IFNα  (100 U/ml) alone or IFNα  together with PD98059 (50 µM). MTT assay was preformed as described in Fig. 1.
The p values were determined by paired t-test. *significantly different (p < 0.01) from the corresponding values in cultures with
IFNα  alone.
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myeloma cells in vitro and protein kinase ERK played a
key role in myeloma cells in response to IFNα .
Materials and methods
Reagents
Human recombinant IFNα  was provided by Institute of
Biotechnology (Beijing, China). Anti-human IL-6R and
gp130 antibodies were prepared in our lab. Anti-ERK and
phospho-ERK antibodies was purchased from Santa Cruz
Biotechnology (USA). Anti-STAT3, STAT1, phospho-
STAT3 and phospho-STAT1 antibodies were purchased
from NEB Biotechnology (USA).
Human myeloma cell lines
Human myeloma cell line U266 was kindly provided by
Prof. Xueguang Zhang (Suzhou University, China). Sko-
007 myeloma cell line was obtained from Medical School
of Stanford University (USA). The cells were maintained
in RPMI1640 medium supplemented with 10% fetal calf
serum, 2 mM L-glutamine, 50 U/ml penicillin and 80 U/
ml streptomycin.
Effect of IFNα  on the growth of myeloma cells
The proliferation of myeloma cells in the presence of
IFNα  was measured by MTT assay as described previously
[7].
Expression of two IL-6 receptor chains (IL-6R and gp130) 
on myeloma cell surface
2 ×  105 myeloma cells were treated with or without IFNα
(100 U/ml) for 48 h and then incubated with anti-IL-6R
or anti-gp130 antibodies for 30 min and with the relevant
FITC-labeled second antibodies for 20 min. Cell samples
were harvested and subjected to FACS analysis.
Activation of the protein kinase ERK and the transcription 
factors STAT3 and STAT1 in myeloma cells induced by 
IFNα
2 ×  106 myeloma cells were treated with IFNα  (100 U/ml)
for 10 min (to detect the activation of STAT3 and STAT1)
or 48 h (to detect the activation of ERK) and then lyzed in
100 µL lysis buffer (10 mM Tris-Cl pH 7.6, 150 mM NaCl,
0.5% NP40, 5 mM EDTA, 1 mM PMSF, 2 mM Na3VO4, 1
mM NaF, 2 µg/mL aprotinin). After 30 min on ice, cell
lysates were cleared by configuration at 12000 ×  g for 30
min at 4°. The concentrations of the cytoplasmic proteins
were measured by Bradford assay [9]. Then 30 µg cyto-
plasmic proteins were separated by 10% polyacrylamide-
SDS gel and transferred elechtrophoretically to Immo-
bilon (Millipore). After blocking with 5% dry milk, the
membranes were blotted with anti-ERK, STAT3, STAT1 or
anti-phospho-ERK, phospho-STAT3, phospho-STAT1 an-
tibodies and the relevant HRP-labeled second antibodies.
Immunoreactive proteins were visualized with an en-
hanced chemiluminescence (ECL) detection system (Am-
ersham, USA).
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